Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants

2. juli 2026 oppdatert av: Chiesi Farmaceutici S.p.A.

An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.

This Phase 1 study evaluates the effect of pantoprazole (a proton pump inhibitor) on the pharmacokinetics (PK) of CHF10196 (Florensocatib) in healthy male participants. Participants receive CHF10196 alone and in combination with pantoprazole to assess potential drug-drug interaction (DDI) effects on systemic exposure.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Intervensjonell

Registrering (Antatt)

18

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Leeds, Storbritannia
        • Fortrea Clinical Research Unit (CRU) Limited
        • Ta kontakt med:
          • Firas Almezedi

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Beskrivelse

Key Inclusion Criteria:

  • BMI (body mass index) between 18.0 and 30.0 kg/m²
  • Weight between 45 and 100 kg
  • Non-smokers or ex-smokers (<5 pack-years)
  • Clinically healthy based on medical history and examination
  • Normal vital signs
  • Normal ECG
  • Willingness to comply with contraception requirements

Key Exclusion Criteria:

  • Recent participation in another clinical study
  • Significant medical conditions
  • Abnormal laboratory values
  • Positive HIV or hepatitis tests
  • Recent infection or COVID-19
  • Drug or alcohol abuse
  • Use of prohibited medications
  • Gastrointestinal surgery affecting absorption
  • Hypersensitivity to study drugs

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196

Treatment Period 1:

CHF10196 single dose administration on Day1;

Treatment Period 2:

CHF10196 single dose administration after pantoprazole single dose administration on Day13

Treatment Period 2:

Pantoprazole single dose administration from Day8 to Day13

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PK parameter: AUC0-∞
Tidsramme: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose
PK parameter: AUC0-t
Tidsramme: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose
PK parameter: Cmax
Tidsramme: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability: Incidence of adverse events (AE)
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Safety and tolerability: Change from baselines for vital signs: PR
Tidsramme: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for vital signs - RR
Tidsramme: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for vital signs - blood pressure
Tidsramme: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for ECG
Tidsramme: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval

Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baseline for ECG (HR)
Tidsramme: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

change from baseline for ECG recording of heart rate (HR)

Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196).

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baseline for laboratory abnormalities
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Number of participants with abnormal blood laboratory test results. Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: AUC0-24h
Tidsramme: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
Additional pharmacokinetic parameters: CL/F
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: t1/2
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: Vd/F
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: tmax
Tidsramme: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

14. oktober 2026

Primær fullføring (Antatt)

9. desember 2026

Studiet fullført (Antatt)

9. desember 2026

Datoer for studieregistrering

Først innsendt

26. juni 2026

Først innsendt som oppfylte QC-kriteriene

2. juli 2026

Først lagt ut (Faktiske)

6. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere